• What Optimized GBA1 mRNA Shows—and Leaves Open

  2026-10-12

  A source-grounded overview of a 2026 study that optimized human GBA1 mRNA, evaluated glucocerebrosidase expression and lysosomal rescue in cell models, and examined enzyme activity in mouse liver and spleen. The findings support proof of concept, but do not establish clinical efficacy, durability, neurological benefit, or long-term safety.

• 4-MUG and the Evidence for GCase mRNA Therapy

  2026-10-12

  4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) provides a fluorescent way to examine glycosidase catalysis, while a 2026 study reported functional glucocerebrosidase expression from optimized GBA1 mRNA in cellular and mouse models. The assay concept is relevant to enzyme activity, but it does not by itself establish lysosomal delivery, disease correction, safety, or clinical efficacy.

• SAN-Plexus Assembloids: Findings and Limits

  2026-10-11

  The supplied Cell Stem Cell report describes human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like tissues to study neuro-cardiac control of pacemaker maturation. Its reported prosaposin–GPR37 signaling result is mechanistically suggestive, but interpretation is bounded by the abstract-level evidence supplied, the engineered nature of the model, and the absence of evidence that isoproterenol was used in the study.

• AP-2α, MGMT, and TMZ Resistance in Recurrent GBM

  2026-10-10

  The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and connects this pathway to temozolomide resistance, DNA damage, and tumor control. Its proposed retinoic acid–RAR/RXR–AP-2α axis provides a mechanistic framework for studying resistance beyond MGMT promoter status alone, while remaining a preclinical finding that requires further validation.

• Cycloastragenol in Glucocorticoid-Induced ONFH

  2026-10-09

  A 2024 in vivo study found that cycloastragenol reduced femoral-head bone loss and necrotic changes in a rat model of methylprednisolone-associated osteonecrosis. The work links these effects to lower osteoclast activity, altered RANKL/OPG signaling, and improved local vascular findings, while clinical translation remains unproven.

• Cimetidine and BBB Assays: Interpreting the 2025 Model

  2026-10-09

  A 2025 Drug Delivery study developed a high-throughput surrogate blood-brain barrier model that combines LLC-PK1-MOCK/MDR1 cells with correction for lysosomal trapping. Its results suggest that permeability, P-glycoprotein efflux, and intracellular sequestration should be interpreted together when prioritizing CNS drug candidates, while remaining cautious about extrapolating the model to individual compounds such as Cimetidine.

• Ertapenem in Resistance Research: Evidence and Limits

  2026-10-08

  Ertapenem is a broad-spectrum carbapenem antibiotic with established mechanistic and pharmacokinetic relevance, but its role in carbapenem-resistance research must be interpreted carefully. Recent Guangdong data show extensive carbapenemase gene carriage and mobility in carbapenem-resistant Enterobacter cloacae, while not directly testing ertapenem susceptibility.

• Human SAN–Plexus Assembloids and Pacemaker Maturation

  2026-10-08

  The reference study develops human pluripotent stem cell-derived sinoatrial node–cardiac plexus assembloids that combine pacemaker, neural, and atrial-like tissues in one model. Its integrated organoid, electrophysiological, and spatial-transcriptomic evidence supports a neuron-to-pacemaker PSAP–GPR37 signaling program associated with pacemaker maturation, while also defining important limits for translation beyond the in vitro system.

• Tariquidar and the Mechanics of Chemoresistance

  2026-10-07

  A mechanistic perspective on how extracellular viscosity may drive P-glycoprotein-linked chemoresistance—and how Tariquidar (XR9576) can help translational researchers distinguish transporter activity from broader mechanobiological stress responses.

• Octyl-α-ketoglutarate in HIF-1α Research

  2026-10-07

  Octyl-α-ketoglutarate is a research tool for examining how α-ketoglutarate availability intersects with prolyl hydroxylase activity, HIF-1α regulation and cancer metabolism. Current evidence supports a biologically plausible connection, but the supplied colorectal cancer study investigated IDH2 rather than the compound itself. This overview separates published findings from supplier claims and outlines key limitations, applicability boundaries and research questions.

• MRSA Extracellular Vesicles and IL-8 in Oral Cancer

  2026-10-06

  A 2026 study reports that extracellular vesicles released by methicillin-resistant Staphylococcus aureus promote oral squamous cell carcinoma growth through an IL-8–CXCR1 signaling axis. Its main contribution is connecting antibiotic resistance-associated bacterial vesicles with ERK/c-Jun signaling and tumor-cell proliferation, while also identifying important boundaries for interpretation, including the need to distinguish MRSA effects from strain-specific vesicle biology.

• Bradykinin Research: Physiology, Evidence and Limits

  2026-10-06

  Bradykinin is an endogenous peptide and endothelium-dependent vasodilator used in research on vascular signaling, permeability, smooth muscle responses, pain, and inflammation. This overview distinguishes established receptor biology from supplier claims, compares evidence across experimental contexts, and explains why findings from a 2025 diabetic-cognition study cannot be extrapolated to Bradykinin.

• Bradykinin: Mechanisms, Evidence, and Research Context

  2026-10-05

  Bradykinin is an endogenous signaling peptide and endothelium-dependent vasodilator studied across vascular biology, permeability, inflammation, pain, and smooth muscle physiology. This overview distinguishes established receptor biology from supplier claims, compares evidence types, and defines the limits of translating experimental findings to human disease.

• Dasatinib and NETs in CML Research

  2026-10-05

  A source-grounded overview of five questions about Dasatinib Monohydrate, BMS-354825, neutrophil extracellular traps and chronic myeloid leukemia research, with emphasis on evidence quality, interpretation and applicability limits.

• Dimetridazole: Research Context and Evidence

  2026-10-03

  Dimetridazole, also known as 1,2-Dimethyl-5-nitroimidazole, sits at the intersection of antimicrobial, environmental-fate, and analytical research. The strongest supplied evidence is a quantum-chemical study of hydroxyl-radical degradation and transformation-product toxicity; claims about quorum sensing, biofilm suppression, combination therapy, and infection-model utility remain insufficiently supported by the cited primary literature.

8014 records 1/535 page Next 12345 下5页 Last page